ATC Group: N02CC Selective serotonin (5HT1) agonists

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N02CC in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N02 Analgesics
3 N02C Antimigraine preparations
4 N02CC Selective serotonin (5HT1) agonists

Group N02CC contents

Code Title
N02CC01 Sumatriptan
N02CC02 Naratriptan
N02CC03 Zolmitriptan
N02CC04 Rizatriptan
N02CC05 Almotriptan
N02CC06 Eletriptan
N02CC07 Frovatriptan
N02CC08
N02CC51

Active ingredients in N02CC

Active Ingredient Description
Almotriptan

Almotriptan is a selective 5-HT1B and 5-HT1D receptor agonist. These receptors mediate vasoconstriction of certain cranial vessels, as demonstrated in studies using isolated human tissue preparations.

Eletriptan

Eletriptan is a selective agonist at the vascular 5-HT1B and neuronal 5-HT1D receptors. Eletriptan also exhibits high affinity for the 5-HT1F receptor which may contribute to its anti-migraine mechanism of action.

Frovatriptan

Frovatriptan is a selective agonist for 5-HT receptors. Frovatriptan is believed to act selectively on extracerebral, intracranial arteries to inhibit the excessive dilatation of these vessels in migraine.

Naratriptan

Naratriptan has been shown to be a selective agonist for 5 hydroxytryptamine1 (5-HT1) receptors mediating vascular contraction. This receptor is found predominantly in intracranial (cerebral and dural) blood vessels. Naratriptan is indicated for the acute treatment of migraine attacks with or without aura.

Rizatriptan

Rizatriptan binds selectively with high affinity to human 5-HT1B and 5-HT1D receptors. The therapeutic activity of rizatriptan in treating migraine headache may be attributed to its agonist effects at 5-HT1B and 5-HT1D receptors on the extracerebral intracranial blood vessels that are thought to become dilated during an attack and on the trigeminal sensory nerves that innervate them.

Sumatriptan

Sumatriptan has been demonstrated to be a specific and selective 5-Hydroxytryptamine1 (5HT1D) receptor agonist with no effect on other 5HT receptor (5-HT2 - 5-HT7) subtypes. The vascular 5-HT1D receptor is found predominantly in cranial blood vessels and mediates vasoconstriction.

Zolmitriptan

Zolmitriptan has been demonstrated to be a selective agonist for the vascular human recombinant 5HT1B and 5HT1D receptor subtypes. Zolmitriptan is a high affinity 5HT1B/1D receptor agonist with modest affinity for 5HT1A receptors.

Related product monographs

Title Information Source Document Type  
ALMOGRAN Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
AMERGE Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
FROVA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
IMIGRAN Nasal spray, solution Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
IMIGRAN Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
IMIGRAN Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
IMITREX Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
IMITREX Nasal spray FDA, National Drug Code (US) MPI, US: SPL/PLR
IMITREX Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
MAXALT Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MIGARD Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NARAMIG Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
RELPAX Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
REYVOW Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
SUMATRAN Tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
ZOMIG Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
ZOMIG Nasal spray Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC